It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The retinal pigment epithelium (RPE) is essential for the survival and function of retinal photoreceptor cells. RPE dysfunction causes various retinal diseases including age-related macular degeneration (AMD). Clinical studies on ES/iPS cell-derived RPE transplantation for RPE dysfunction-triggered diseases are currently underway. Quantification of the diseased RPE area is important to evaluate disease progression or the therapeutic effect of RPE transplantation. However, there are no standard protocols. To address this issue, we developed a 2-step software that enables objective and efficient quantification of RPE-disease area changes by analyzing the early-phase hyperfluorescent area in fluorescein angiography (FA) images. We extracted the Abnormal region. This extraction was based on deep learning-based discrimination. We scored the binarized extracted area using an automated program. Our program’s performance for the same eye from the serial image captures was within 3.1 ± 7.8% error. In progressive AMD, the trend was consistent with human assessment, even when FA images from two different visits were compared. This method was applicable to quantifying RPE-disease area changes over time, evaluating iPSC-RPE transplantation images, and a disease other than AMD. Our program may contribute to the assessment of the clinical course of RPE-disease areas in routine clinics and reduce the workload of researchers.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Kobe City Eye Hospital, Kobe, Japan; Kyoto University Graduate School of Medicine, Department of Ophthalmology and Visual Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
2 RIKEN Center for Biosystems Dynamics Research, Laboratory for Biologically Inspired Computing, Suita, Japan (GRID:grid.508743.d)
3 Kobe City Eye Hospital, Kobe, Japan (GRID:grid.508743.d)
4 Epistra Inc., Minato-ku, Japan (GRID:grid.508743.d)
5 Kobe City Eye Hospital, Kobe, Japan (GRID:grid.508743.d); RIKEN Center for Biosystems Dynamics Research, Laboratory for Biologically Inspired Computing, Suita, Japan (GRID:grid.508743.d)
6 Kyoto University Graduate School of Medicine, Department of Ophthalmology and Visual Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
7 Kobe City Eye Hospital, Kobe, Japan (GRID:grid.508743.d); VCCT Inc., Kobe, Japan (GRID:grid.508743.d)